PURPOSE:Local progression, in patients with hormone-refractory prostate cancer, often causes significant morbidity.
Pelvic radiotherapy (RT) provides effective palliation in this setting, with most published studies supporting the use of high-dose regimens. The aim of the present study was to examine the role of split-course hypofractionated RT used at our institution in treating this group of patients.
METHODS AND MATERIALS: A total of 34 men with locoregionally progressive hormone-refractory prostate cancer, treated with a split course of pelvic RT (45-60 Gy in 18-24 fractions) between 2000 and 2008 were analyzed. The primary endpoints were the response rate and actuarial locoregional progression-free survival. Secondary endpoints included overall survival, compliance, and acute and late toxicity.
RESULTS: The median age was 71 years (range, 53-88). Treatment resulted in an overall initial response rate of 91%, a median locoregional progression-free survival of 43 months, and median overall survival of 28 months. Compliance was excellent and no significant late toxicity was reported.
CONCLUSIONS: The split course pelvic RT described has an acceptable toxicity profile, is effective, and compares well with other high-dose palliative regimens that have been previously reported.
Gogna NK, Baxi S, Hickey B, Baumann K, Burmeister E, Holt T. Are you the author?
Radiation Oncology Services, Mater Centre, Brisbane, Queensland, Australia.
Reference: Int J Radiat Oncol Biol Phys. 2012 Feb 16. Epub ahead of print.